FDA
-
-
-
-
-
-
-
Prime Medicine (PRME) Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition
-
-
-
-
-
-
-
Citi Upgrades Prime Medicine (PRME) to Buy
-
-
-
-
-
-
-
Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates
-
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

